Manta Ray Ventures is a London-based early-stage venture capital firm that invests globally across healthcare, deep tech, and sustainability. It typically backs companies from pre-seed through Series B and is known for a flexible, patient-capital model supported by family office backing. That structure allows it to support companies over longer horizons than many conventional VC funds.

Its neuro-relevant portfolio includes companies such as Kernel and Juvena Therapeutics, showing interest in both neurotechnology and adjacent neuromuscular or biotech spaces. Manta Ray is not a neuro-only investor, but it has shown willingness to back technically ambitious, science-heavy businesses addressing major unmet needs. Its style is especially attractive for founders who need time and flexibility rather than narrow short-term milestones.

The firm invests internationally, with strongest presence in the UK, US, and Central Europe. For neurotech, it is relevant to founders building early-stage science-driven platforms that benefit from long-duration support and open-minded sector coverage. It is especially interesting where neurotechnology sits alongside broader deep-tech or biotech narratives.